ADMA Biologics (ADMA) Announces Proposed $75M Share Common Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
Go back to ADMA Biologics (ADMA) Announces Proposed $75M Share Common Offering
February 7, 2020 6:10 AM EST
ADMA Biologics, Inc. (NASDAQ: ADMA) an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases, today announced the pricing of its previously announced underwritten public offering of 23,500,000 shares... More
February 6, 2020 6:01 PM EST
After-Hours Stock Movers
Assertio Therapeutics, Inc. (NASDAQ: ASRT) 51% HIGHER; entered into a definitive agreement (Agreement) with Collegium Pharmaceutical, Inc. (Nasdaq: COLL) pursuant to which Collegium will acquire the NUCYNTA® franchise of products from the Company. The closing of the agreement is expected by February 14, 2020.
Zogenix, Inc. (NASDAQ: ZGNX) 33% LOWER; reported positive top-line results from its global Phase 3 clinical trial (Study 1601) of its lead investigational therapy, FINTEPLA® (ZX008, fenfluramine oral solution) in... More
February 6, 2020 4:09 PM EST
ADMA Biologics, Inc. (Nasdaq: ADMA) announced that it has commenced an $75 million underwritten public offering of its common stock. The Company intends to grant the underwriters of the offering a 30-day option to purchase up to an additional 15 percent of the number of... More
